中国P站

Cancer therapy; DNA damage response; Tumor microenvironment; Epigenetics; Immune checkpoint blockade; Metabolic reprogramming; Liquid biopsy; RNA-based therapies; CRISPR/Cas9; Single-cell sequencing

Introduction

Current cancer research extensively investigates how malignant cells effectively exploit DNA damage response (DDR) pathways, which are critical for their survival and proliferation. This exploitation presents significant therapeutic opportunities, where targeting these pathways with specific inhibitors shows promise. Studies detail the mechanisms of action for various DDR inhibitors and assess their effectiveness in overcoming the common problem of resistance to conventional cancer treatments, thereby offering strategic insights into novel combination therapies that could enhance patient responses and outcomes[1].

Beyond the cellular intrinsic mechanisms, the broader tumor microenvironment (TME) is increasingly recognized for its profound and complex influence on cancer progression, metastasis, and the development of therapeutic resistance. The intricate interplay among various cellular and non-cellular components within the TME is crucial, as they collectively create a supportive niche that actively promotes tumor growth. Understanding this dynamic environment is leading to the development of innovative strategies specifically aimed at targeting the TME, with the goal of significantly enhancing the efficacy of existing and future cancer therapies[2].

Epigenetic alterations, encompassing DNA methylation, histone modification, and the actions of non-coding RNAs, are now understood to play a pivotal and driving role in the initiation and progression of cancer. These significant changes contribute directly to oncogenesis by altering gene expression without changing the underlying DNA sequence. This recognition is critical for identifying and developing promising epigenetic therapies that precisely target these aberrant modifications, offering new avenues for effective cancer treatment strategies[3].

Resistance to immune checkpoint blockade (ICB) therapies represents a major, ongoing challenge in the clinical management of various cancers. Comprehensive investigations are focused on unraveling the molecular underpinnings of this resistance. These studies explore diverse mechanisms, including specific alterations within tumor cells, the complex interactions occurring in the tumor microenvironment, and the influence of host factors. Such a comprehensive overview is essential for understanding how cancers effectively evade immune surveillance and for designing potential strategies to overcome this formidable resistance, thereby improving the long-term success of immunotherapy[4].

A hallmark of cancer cells is their fundamental shift in metabolism, termed metabolic reprogramming, which directly supports their characteristic rapid growth and uncontrolled proliferation. This involves significant alterations in glucose, lipid, and amino acid metabolism, all of which contribute profoundly to oncogenesis. Researchers are actively exploring the immense potential of specifically targeting these altered metabolic pathways, envisioning them as novel and highly effective therapeutic strategies to disrupt cancer cell survival and expansion[5].

Recent advancements in liquid biopsy are profoundly transforming the landscape of cancer diagnosis, prognosis, and the implementation of precision medicine. This non-invasive technology emphasizes the precise detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other crucial biomarkers from patient blood samples. These developments highlight the revolutionary potential of liquid biopsy to fundamentally change non-invasive cancer management, allowing for earlier detection, more accurate staging, and personalized treatment guidance tailored to individual patient profiles[6].

The rapidly burgeoning field of RNA-based therapies in cancer holds immense promise, introducing a new class of treatments. This includes innovative approaches such as messenger RNA (mRNA) vaccines, small interfering RNA (siRNA), microRNA (miRNA), and circular RNA (circRNA) therapeutics. Extensive research is dedicated to understanding their intricate underlying molecular mechanisms, addressing critical delivery challenges, and evaluating their significant clinical potential in precisely targeting oncogenic pathways and effectively enhancing anti-tumor immunity[7].

CRISPR/Cas9 gene editing technology is emerging as a truly transformative tool in cancer therapy. Its diverse applications focus on precisely targeting specific oncogenes, correcting deleterious mutations, and significantly enhancing the body's natural anti-tumor immune responses. While the current advancements are considerable, ongoing discussions address existing challenges such as potential off-target effects and efficient delivery methods, all of which are crucial considerations for successfully translating this powerful technology into safe and effective clinical practice for cancer patients[8].

Single-cell sequencing technologies are fundamentally revolutionizing cancer research by revealing unprecedented details. These advanced techniques effectively unveil cellular heterogeneity within complex tumors, enabling the identification of rare but significant cell populations, and allowing for the meticulous dissection of intricate molecular mechanisms at an unparalleled resolution. These applications are proving invaluable for understanding tumor evolution, unraveling the complexities of drug resistance, and ultimately guiding the development of highly personalized cancer therapies[9].

Central to cellular regulation, the crucial PI3K/AKT/mTOR signaling pathway acts as a key orchestrator of cell growth, survival, and metabolism. This pathway is frequently found to be dysregulated in various cancers, making it a prime therapeutic target. However, effectively targeting this complex pathway presents its own set of challenges. Research actively highlights significant opportunities for developing more potent and selective inhibitors, as well as innovative combination therapies, all with the ultimate goal of improving patient outcomes by effectively disrupting this critical cancer-promoting pathway[10].

Description

Cancer's survival often hinges on its ability to manipulate fundamental cellular processes. One such mechanism involves the exploitation of DNA damage response (DDR) pathways by cancer cells, enabling their unchecked survival and proliferation. Understanding how these pathways are hijacked opens doors for therapeutic interventions. Specifically, various DDR inhibitors and their mechanisms are being rigorously studied for their potential to overcome resistance to conventional cancer treatments, suggesting promising new combination strategies that can enhance efficacy and improve patient outcomes [1]. In parallel, epigenetic alterations like DNA methylation, histone modification, and the influence of non-coding RNAs are increasingly recognized as primary drivers of cancer development and progression. These changes contribute significantly to oncogenesis, highlighting epigenetic therapies as a vital area for targeting these aberrant modifications to effectively treat cancer [3].

Beyond intrinsic cellular processes, the tumor microenvironment (TME) plays a pivotal and complex role in shaping cancer progression, metastasis, and the development of therapeutic resistance. The TME, a dynamic ecosystem of diverse cellular and non-cellular components, actively fosters a supportive niche for tumor growth. This understanding is crucial for devising new strategies aimed at targeting the TME itself, which could significantly enhance the overall effectiveness of cancer therapies [2]. Furthermore, cancer cells exhibit a unique metabolic reprogramming, fundamentally altering their glucose, lipid, and amino acid metabolism to fuel their rapid growth and proliferation. These metabolic shifts are crucial for oncogenesis, and current research focuses on exploiting these distinct metabolic pathways as novel therapeutic targets to disrupt cancer cell viability and progression [5].

A significant hurdle in modern oncology is the resistance to immune checkpoint blockade (ICB) therapies. Investigations delve into the intricate molecular mechanisms underlying this resistance, which include alterations in tumor cells, the tumor microenvironment, and host factors. This comprehensive analysis is essential for understanding how cancers effectively evade immune surveillance and for developing proactive strategies to overcome this pervasive resistance [4]. Similarly, the PI3K/AKT/mTOR signaling pathway is a critical regulator of cell growth, survival, and metabolism, frequently found to be dysregulated in numerous cancers. While targeting this complex pathway presents challenges, it also offers substantial opportunities for developing more effective inhibitors and innovative combination therapies aimed at improving patient outcomes by disrupting this central oncogenic cascade [10].

The landscape of cancer therapy is being transformed by emerging molecular technologies. RNA-based therapies, including mRNA vaccines, siRNA, miRNA, and circRNA therapeutics, represent a burgeoning field. Research explores their precise molecular mechanisms, tackles delivery challenges, and assesses their considerable clinical potential to target specific oncogenic pathways and bolster anti-tumor immunity [7]. Complementing this, CRISPR/Cas9 technology is demonstrating transformative potential in gene editing for cancer therapy. Its applications range from targeting specific oncogenes and correcting mutations to enhancing the body’s own immune responses against tumors. While significant advancements are apparent, ongoing efforts are addressing challenges such as off-target effects and efficient delivery methods to ensure its safe and effective translation into clinical practice [8].

Revolutionizing both cancer diagnosis and research are advanced technological platforms. Liquid biopsy, in particular, is gaining prominence for its application in cancer diagnosis, prognosis, and guiding precision medicine. This non-invasive method focuses on detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other valuable biomarkers, promising a paradigm shift in non-invasive cancer management [6]. Concurrently, single-cell sequencing technologies are fundamentally changing cancer research by offering an unprecedented resolution. These tools reveal cellular heterogeneity within tumors, identify rare cell populations, and meticulously dissect complex molecular mechanisms, providing invaluable insights into tumor evolution, drug resistance, and enabling the development of truly personalized cancer therapies [9].

Conclusion

This collection of articles offers a comprehensive look at modern cancer research and therapy, emphasizing both the fundamental biological processes driving the disease and cutting-edge therapeutic and diagnostic advancements. Key discussions revolve around how cancer cells exploit DNA damage response (DDR) pathways for survival, presenting opportunities for targeted inhibitors and combination strategies to overcome treatment resistance. The complex interplay within the tumor microenvironment (TME) is highlighted as a critical factor in cancer progression, metastasis, and therapy evasion, suggesting that targeting the TME could significantly improve outcomes. Epigenetic alterations, including DNA methylation and histone modification, are identified as major drivers of oncogenesis, paving the way for epigenetic therapies. Resistance to immune checkpoint blockade (ICB) therapies remains a significant challenge, with studies exploring various mechanisms within tumor cells, the TME, and host factors to develop strategies for overcoming immune evasion. Cancer's metabolic reprogramming, involving altered glucose, lipid, and amino acid metabolism, is another area being investigated for novel therapeutic interventions. Diagnostic advancements like liquid biopsy, focusing on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), promise to revolutionize non-invasive cancer management and personalize medicine. Emerging therapeutic modalities include RNA-based therapies, such as mRNA vaccines and siRNA, targeting oncogenic pathways, alongside the transformative potential of CRISPR/Cas9 gene editing for correcting mutations and enhancing anti-tumor immunity. Finally, single-cell sequencing is revolutionizing research by dissecting tumor heterogeneity and evolution, while the PI3K/AKT/mTOR signaling pathway is explored as a frequent dysregulated target with both challenges and opportunities for new inhibitors.

References

1. Yuxian F, Jun Y, Xiang L (2023) .J Exp Clin Cancer Res 42:232.

   , ,

2. Jinhu Y, Jie D, Ruoxian W (2023) .Biomolecules 13:1092.

   , ,

3. Xiaojun L, Mingxi L, Yu Z (2022) .Front Oncol 12:876930.

   , ,

4. Yu-Hui S, Hong-Wei L, Dong-Bing Z (2023) .Front Immunol 14:1118182.

   , ,

5. Yanan Z, Yaxuan W, Xiaoman W (2022) .J Exp Clin Cancer Res 41:119.

   , ,

6. Yidan J, Yanfei Y, Junqiang C (2023) .J Exp Clin Cancer Res 42:172.

   , ,

7. Xiaowei H, Yuqin L, Mingyue W (2023) .Mol Cancer 22:13.

   , ,

8. Yating H, Huimei C, Fan Z (2023) .J Exp Clin Cancer Res 42:133.

   , ,

9. Mengmeng X, Jinyu Y, Zhihui L (2023) .J Exp Clin Cancer Res 42:290.

   , ,

10. Yuzhu L, Xiaolin L, Junnan Z (2023) .Pharmacol Res 191:106757.

    , ,